MedTrace Logo

The Effects of JNJ-39393406 on Psychometric Performance and Residual Depressive

NCT02677207 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2020-05-22

No results posted yet for this study

Summary

To evaluate the effects of the nicotinic allosteric modulator JNJ-39393406 on psychometric performance and residual depressive symptoms in patients who have been diagnosed with unipolar and bipolar depression but currently DO NOT meet criteria for an episode of Major Depression or Manic Episode.

Conditions

Interventions

DRUG

JNJ-39393406

JNJ-39393406 100 mg capsules or placebo daily for the first week and 200 mg daily for the rest of the trial

DRUG

Placebo

JNJ-39393406 100 mg capsules or placebo daily for the first week and 200 mg daily for the rest of the trial

Sponsors & Collaborators

  • Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

    collaborator INDUSTRY

  • Tangent Data

    lead OTHER

Principal Investigators

  • Michael Davidson, M.D. · Principal Investigator

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2017-05-31
Completion
2017-07-31

Countries

  • Moldova
  • Romania

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02677207 on ClinicalTrials.gov